Sastasundar Ventures Limited has informed the Exchange regarding Outcome of Board Meeting held on February 26, 2026 regarding in-principle approval of Scheme of Arrangement by the Board of Directors of Health X Platform Limited (formerly known as Sastasundar Ventures Limited)
HEALTHX · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Health X Platform Limited's Board has given in-principle approval for a restructuring (merger/demerger) under a court-sanctioned scheme of arrangement, under which its material subsidiary Sastasundar Healthbuddy Limited (SHBL) will ultimately be merged into HealthX. The goal is to create separate, independent group structures for the company's healthcare and financial services businesses, with the aim of keeping SHBL shareholders' economic interest intact, subject to final valuation. The restructuring is contingent on Mitsubishi Corporation selling its entire stake in SHBL to Envision India Fund (a QIB) under a share purchase agreement dated February 25, 2026. Final swap ratio, valuation and approvals from the Board, Audit Committee and Independent Directors are still pending, and implementation is expected in the next financial year after FY25-26 accounts are finalized.
This is only an initial, conditional approval and not a confirmed merger yet, so it should not move the stock materially today. If completed, the merger would simplify the group structure by consolidating SHBL into the listed entity, but shareholders should watch for the final swap ratio, valuation report, and subsequent NCLT/regulatory approvals before drawing conclusions.